99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: Pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer

Journal of Nuclear Medicine

Volumn 55, Issue 11, 2014, Pages 1791-1798

  Vallabhajosula, Shankar ^a,d   Nikolopoulou, Anastasia ^a   Babich, John W ^b   Osborne, Joseph R ^a   Tagawa, Scott T ^a   Lipai, Irina ^a   Solnes, Lilja ^a   Maresca, Kevin P ^b   Armor, Thomas ^b   Joyal, John L ^b   Crummet, Robert ^b   Stubbs, James B ^c   Goldsmith, Stanley J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Clinical Research   (United States)

^c Siemens Medical Solutions USA Inc   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

99mTc MIP 1404; 99mTc MIP 1405; Molecular imaging; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

MIP 1405 TC 99M; NEW DRUG; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TROFOLASTAT TC 99M; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TECHNETIUM; TECHNETIUM 99M 1-(1-(2-(BIS(CARBOXYMETHYL)AMINO)-2-OXOETHYL)-1H-IMIDAZOL-2-YL)-2-((1-(2-(BIS(CARBOXYMETHYL)AMINO)-2-OXOETHYL)-1H-IMIDAZOL-2-YL)METHYL)-9,14-DIOXO-2,8,13,15-TETRAAZAOCTADECANE-7,12,16,18-TETRACARBOXYLIC ACID); TECHNETIUM 99M 7-AMINO-1-(1-(CARBOXYMETHYL)-1H-IMIDAZOL-2-YL)-2-((1-(CARBOXYMETHYL)-1H-IMIDAZOL-2-YL)METHYL)-8,16-DIOXO-2,9,15,17-TETRAAZAICOSANE-14,18,20-TRICARBOXYLIC ACID); TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; BLADDER; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; GAMMA CAMERA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; KIDNEY; LACRIMAL GLAND; LIVER; LYMPH NODE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METASTASIS; METASTATIC PROSTATE CANCER; PAROTID GLAND; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE DEFECT; WHOLE BODY IMAGING; CLINICAL TRIAL; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; PATIENT SAFETY; PROCEDURES; PROSTATE TUMOR; RADIOMETRY; SCINTISCANNING; TIME; TREATMENT OUTCOME;

AGED; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOTECHNETIUM COMPOUNDS; PATIENT SAFETY; PROSTATIC NEOPLASMS; RADIOMETRY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TECHNETIUM; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84910675926     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.140426     Document Type: Article

References (37)

1. Siegel R, Ma J, Zou Z, Jemal J. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9-29.
2. Surveillance Research Program, NCI. SEER Stat Fact Sheets: Prostate Cancer. National Cancer Institute website. http://seer.cancer.gov/statfacts/html/prost. html. Accessed October 3, 2014.
3. Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. Can J Urol. 2008;15:4363-4374.
4. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28-53.
5. Hou AH, Swanson D, Barqawi AB. Modalities for imaging of prostate cancer. Adv Urol. 2009;2009:1-12.
6. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68-80.
7. Toegel S, Hoffmann O, Wadsak W, et al. Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging. 2006;33:491-494.
8. Ghosh A, Heston WDW. Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
9. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding prostate-specific membrane antigen. Cancer Res. 1993; 53:227-230.
10. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927-935.
11. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
12. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.
13. Wright GL Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
15. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362.
16. Vallabhajosula S, Kuji I, Hamacher KA, et al. Pharmacokinetics and biodistribution of 111In-And 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005;46:634-641.
17. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial results of lutetium-177 labeled J591, a monoclonal antibody to PSMA in patients with androgenindependent prostate cancer. J Clin Oncol. 2005;23:4591-4601.
18. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostatespecific membrane antigen, in patients. J Nucl Med. 2012;53:1883-1891.
19. Afshar-Oromieh A, Zechmann CM, Malcher A. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
20. Tiffany CW, Lapidus RG, Merion A, et al. Characterization of the enzymatic activity of PSMA: comparison with brain NAALADase. Prostate. 1999;39:28-35.
21. Pinto JT, Suffoletto BP, Bergin TM. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996; 2:1445-1451.
22. Stoermer D, Liu Q, Hall MR, et al. Synthesis and biological evaluation of hydroxamate-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003;13:2097-2100.
23. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate-specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347-357.
24. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamateurea-lysine analogs that target prostate specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932-6940.
25. Maresca KP, Hillier SM, Lu G, et al. Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: effects of chelate design on pharmacokinetics. Inorg Chim Acta. 2012;389:168-175.
26. Hillier SM, Maresca KP, Lu G, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369-1376.
27. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of two high-Affinity PSMA-Avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380-387.
28. Vallabhajosula S, Osborne JR, Nikolopoulou A, et al. Novel 99mTc-labeled small molecule inhibitors of prostate specific membrane antigen (PSMA): initial experience in healthy volunteers and men with metastatic prostate adenocarcinoma (PCa) [abstract]. Eur J Nucl Med Mol Imaging. 2011;38(suppl 2):S202.
29. Lu G, Maresca KP, Hillier SM, et al. Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. 2013;23:1557-1563.
30. The SAAM Institute, Inc. The SAAM Institute website. http://www.saam.com. Accessed October 8, 2014.
31. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294-310.
32. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
33. Cloutier RJ, Smith SA, Watson EE, et al. Dose to the fetus from radionuclides in the bladder. Health Phys. 1973;25:147-161.
34. International Commission on Radiological Protection. Limits for Intakes of Radionuclides by Workers. ICRP publication New York, NY: Pergamon Press; 1979.
35. Eder M, Eisenhut M, Babich JW, Haberkorn U. PSMA as a target for radiolabeled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819-823.
36. Vallabhajosula S, Osborne JR, Nikolopoulou A, et al. PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer (PCa): phase I studies with 99mTc-MIP-1404 [abstract]. J Nucl Med. 2013;54(suppl 2):281.
37. Goffin K, Joniau S, Tenke P, et al. A phase 2 study of 99mTc-trofolastat (MIP-1404) to identify prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection: an interim analysis [abstract]. J Nucl Med. 2014;55(suppl 1):15.